This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-05 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
== Activity and Specificity == In common with most enzymes in family C1, caricain accepts hydrophobic amino acid residues in both S2 and S3. However, other residues are also accommodated in these subsites, including proline in S2, and lysine in S3. The specificities of three cysteine endopeptidases from papaya latex were found to be very similar. Caricain and chymopapain appeared to prefer an aliphatic to a hydrophobic residue at P2. The similarity in specificity of caricain and chymopapain was demonstrated by the fact that, of 44 peptide bonds in manatee hemoglobin cleaved by caricain, 29 were also cleaved by chymopapain. An earlier study had highlighted the similarity in specificity of caricain, chymopapain and papain. All seven bonds of the oxidized B chain of insulin that were hydrolyzed by caricain were also cleaved by papain, and six were hydrolyzed by chymopapain. Caricain can be assayed with Bz-ArgkNHPhNO2, kcat/Km being 187 M21 s21 at pH 6.8 and 40˚C. More sensitive substrates may employ a fluorometric leaving group, kcat/Km for the hydrolysis of Z-Phe-ArgkNHMec being 1.06 3 106 M21 s21 (pH 6.8, 40˚C). The enzyme exhibits a broad pH-activity profile, with the optimum near 7.0. About half-maximal activity is still achieved at pH values of about 5.3 and 8.3, and the profile is reported to be governed by at least three ionizing groups. The active-site sulfur requires reduction for catalytic competence, and this is best achieved by the inclusion of low millimolar concentrations of cysteine in assay buffers.
== How it works == GPC is a type of chromatography in which analytes are separated, based on their size or hydrodynamic volume (radius of gyration). This differs from other chromatographic techniques, which depend upon chemical or physical interactions between the mobile and stationary phases to separate analytes. Separation occurs via the use of porous gel beads packed inside a column (see stationary phase (chemistry)). The principle of separation relies on the differential exclusion or inclusion of the macromolecules by the porous gel stationary phase. Larger molecules are excluded from entering the pores and elute earlier, while smaller molecules can enter the pores, thus staying longer inside the column. The entire process takes place without any interaction of the analytes with the surface of the stationary phase. The smaller analytes relative to the pore sizes can permeate these pores and spend more time inside the gel particles, increasing their retention time. Conversely, larger analytes relative to the pores sizes spend little if any time inside the column, hence they elute sooner. Each type of column has a range of molecular weights that can be separated, according to their pores sizes. If an analyte is too large relative to the column's pores, it will not be retained at all and will be totally excluded; conversely, if the analyte is small relative to the pores sizes, it will be totally permeating.
== Reception and publication == Fleming's discovery was initially regarded as unimportant. Even as he showed his culture plates to his colleagues, all he received was an indifferent response. He described the discovery on 13 February 1929 before the Medical Research Club. His presentation, titled "A medium for the isolation of Pfeiffer's bacillus", did not receive any particular attention. In 1929, Fleming reported his findings to the British Journal of Experimental Pathology on 10 May 1929, and published them in the next month's issue. His article failed to attract any serious attention. Fleming himself was quite unsure of the medical application of his work and was more concerned with its application for bacterial isolation, as he concluded:
Sources: en.wikipedia.org
== Purpose == Breakthrough T1D was founded to support and accelerate breakthroughs in medical science to cure, prevent, and treat type 1 diabetes and its complications. These goals are pursued both through scientific research and public advocacy campaigns.
=== Pharmacodynamics === Nalorphine acts at two opioid receptors — the μ-opioid receptor (MOR) where it has antagonistic effects, and at the κ-opioid receptor (KOR) (Ki = 1.6 nM; EC50 = 483 nM; Emax = 95%) where it exerts high-efficacy partial agonist/near-full agonist characteristics.
The primary function of muscle tissue is contraction. The three types of muscle tissue (skeletal, cardiac and smooth) have significant differences. However, all three use the movement of actin against myosin to create contraction.
== Metabolic pathways and products == Zearalenone is metabolically transformed to α-zearalenol (α-Zel) or (α-Zol), β-zearalenol (β-Zel) or (β-Zol), α-zearalanol (α-Zal), β-zearalanol (β-Zal), and zearalanone (ZAN) in animals. The relative composition of these metabolic products varies by species. In pigs, cows and ducks, α-Zel is the dominant form detected. In humans, both α-Zel and β-Zel are seen in urine samples, with the beta form being prevalent. In chickens, β-Zel is the dominant form and in plant cells, the metabolic product zeralenonne-14-O-β-glucoside has been detected. Additionally, in the organs of animals these metabolic products are further modified to yield zearalenone-14-glucuronide (ZEN-14GlcA), α-zearalenol-glucuronide (α-Zel-14G) and β-zearalenol-glucuronide (β-Zel-14G).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.